Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism

Qiong Liu, Chris T. Harvey, Hao Geng, Changhui Xue, Vivian Chen, Tomasz (Tom) Beer, Zheng (David) Qian

    Research output: Contribution to journalArticle

    23 Citations (Scopus)

    Abstract

    Background: Resistance to chemotherapy represents a significant obstacle in prostate cancer therapeutics. Novel mechanistic understandings in cancer cell chemotherapeutic sensitivity and resistance can optimize treatment and improve patient outcome. Molecular alterations in the metabolic pathways are associated with cancer development; however, the role of these alterations in chemotherapy efficacy is largely unknown. Methods: In a bed-side to bench-side reverse translational approach, we used cDNA microarray and qRT-PCR to identify genes that are associated with biochemical relapse after chemotherapy. Further, we tested the function of these genes in cell proliferation, metabolism, and chemosensitivity in prostate cancer cell lines. Results: We report that the gene encoding mitochondrial malate dehydrogenase 2 (MDH2) is overexpressed in clinical prostate cancer specimens. Patients with MDH2 overexpression had a significantly shorter period of relapse-free survival (RFS) after undergoing neoadjuvant chemotherapy. To understand the molecular mechanism underlying this clinical observation, we observed that MDH2 expression was elevated in prostate cancer cell lines compared to benign prostate epithelial cells. Stable knockdown of MDH2 via shRNA in prostate cancer cell lines decreased cell proliferation and increased docetaxel sensitivity. Further, MDH2 shRNA enhanced docetaxel-induced activations of JNK signaling and induced metabolic inefficiency. Conclusion: Taken together, these data suggest a novel function for MDH2 in prostate cancer development and chemotherapy resistance, in which MDH2 regulates chemotherapy-induced signal transduction and oxidative metabolism.

    Original languageEnglish (US)
    Pages (from-to)1028-1037
    Number of pages10
    JournalProstate
    Volume73
    Issue number10
    DOIs
    StatePublished - Jul 2013

    Fingerprint

    docetaxel
    Malate Dehydrogenase
    Prostatic Neoplasms
    Drug Therapy
    Cell Line
    Small Interfering RNA
    Cell Proliferation
    Recurrence
    Mitochondrial Genes
    Metabolic Networks and Pathways
    Oligonucleotide Array Sequence Analysis
    Genes
    Prostate
    Signal Transduction
    Neoplasms

    Keywords

    • chemotherapy response
    • docetaxel
    • JNK
    • MDH2
    • metabolism

    ASJC Scopus subject areas

    • Urology
    • Oncology

    Cite this

    Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism. / Liu, Qiong; Harvey, Chris T.; Geng, Hao; Xue, Changhui; Chen, Vivian; Beer, Tomasz (Tom); Qian, Zheng (David).

    In: Prostate, Vol. 73, No. 10, 07.2013, p. 1028-1037.

    Research output: Contribution to journalArticle

    Liu, Qiong ; Harvey, Chris T. ; Geng, Hao ; Xue, Changhui ; Chen, Vivian ; Beer, Tomasz (Tom) ; Qian, Zheng (David). / Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism. In: Prostate. 2013 ; Vol. 73, No. 10. pp. 1028-1037.
    @article{3f57ab9e1d794067a223c7eaed57a1b4,
    title = "Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism",
    abstract = "Background: Resistance to chemotherapy represents a significant obstacle in prostate cancer therapeutics. Novel mechanistic understandings in cancer cell chemotherapeutic sensitivity and resistance can optimize treatment and improve patient outcome. Molecular alterations in the metabolic pathways are associated with cancer development; however, the role of these alterations in chemotherapy efficacy is largely unknown. Methods: In a bed-side to bench-side reverse translational approach, we used cDNA microarray and qRT-PCR to identify genes that are associated with biochemical relapse after chemotherapy. Further, we tested the function of these genes in cell proliferation, metabolism, and chemosensitivity in prostate cancer cell lines. Results: We report that the gene encoding mitochondrial malate dehydrogenase 2 (MDH2) is overexpressed in clinical prostate cancer specimens. Patients with MDH2 overexpression had a significantly shorter period of relapse-free survival (RFS) after undergoing neoadjuvant chemotherapy. To understand the molecular mechanism underlying this clinical observation, we observed that MDH2 expression was elevated in prostate cancer cell lines compared to benign prostate epithelial cells. Stable knockdown of MDH2 via shRNA in prostate cancer cell lines decreased cell proliferation and increased docetaxel sensitivity. Further, MDH2 shRNA enhanced docetaxel-induced activations of JNK signaling and induced metabolic inefficiency. Conclusion: Taken together, these data suggest a novel function for MDH2 in prostate cancer development and chemotherapy resistance, in which MDH2 regulates chemotherapy-induced signal transduction and oxidative metabolism.",
    keywords = "chemotherapy response, docetaxel, JNK, MDH2, metabolism",
    author = "Qiong Liu and Harvey, {Chris T.} and Hao Geng and Changhui Xue and Vivian Chen and Beer, {Tomasz (Tom)} and Qian, {Zheng (David)}",
    year = "2013",
    month = "7",
    doi = "10.1002/pros.22650",
    language = "English (US)",
    volume = "73",
    pages = "1028--1037",
    journal = "Prostate",
    issn = "0270-4137",
    publisher = "Wiley-Liss Inc.",
    number = "10",

    }

    TY - JOUR

    T1 - Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism

    AU - Liu, Qiong

    AU - Harvey, Chris T.

    AU - Geng, Hao

    AU - Xue, Changhui

    AU - Chen, Vivian

    AU - Beer, Tomasz (Tom)

    AU - Qian, Zheng (David)

    PY - 2013/7

    Y1 - 2013/7

    N2 - Background: Resistance to chemotherapy represents a significant obstacle in prostate cancer therapeutics. Novel mechanistic understandings in cancer cell chemotherapeutic sensitivity and resistance can optimize treatment and improve patient outcome. Molecular alterations in the metabolic pathways are associated with cancer development; however, the role of these alterations in chemotherapy efficacy is largely unknown. Methods: In a bed-side to bench-side reverse translational approach, we used cDNA microarray and qRT-PCR to identify genes that are associated with biochemical relapse after chemotherapy. Further, we tested the function of these genes in cell proliferation, metabolism, and chemosensitivity in prostate cancer cell lines. Results: We report that the gene encoding mitochondrial malate dehydrogenase 2 (MDH2) is overexpressed in clinical prostate cancer specimens. Patients with MDH2 overexpression had a significantly shorter period of relapse-free survival (RFS) after undergoing neoadjuvant chemotherapy. To understand the molecular mechanism underlying this clinical observation, we observed that MDH2 expression was elevated in prostate cancer cell lines compared to benign prostate epithelial cells. Stable knockdown of MDH2 via shRNA in prostate cancer cell lines decreased cell proliferation and increased docetaxel sensitivity. Further, MDH2 shRNA enhanced docetaxel-induced activations of JNK signaling and induced metabolic inefficiency. Conclusion: Taken together, these data suggest a novel function for MDH2 in prostate cancer development and chemotherapy resistance, in which MDH2 regulates chemotherapy-induced signal transduction and oxidative metabolism.

    AB - Background: Resistance to chemotherapy represents a significant obstacle in prostate cancer therapeutics. Novel mechanistic understandings in cancer cell chemotherapeutic sensitivity and resistance can optimize treatment and improve patient outcome. Molecular alterations in the metabolic pathways are associated with cancer development; however, the role of these alterations in chemotherapy efficacy is largely unknown. Methods: In a bed-side to bench-side reverse translational approach, we used cDNA microarray and qRT-PCR to identify genes that are associated with biochemical relapse after chemotherapy. Further, we tested the function of these genes in cell proliferation, metabolism, and chemosensitivity in prostate cancer cell lines. Results: We report that the gene encoding mitochondrial malate dehydrogenase 2 (MDH2) is overexpressed in clinical prostate cancer specimens. Patients with MDH2 overexpression had a significantly shorter period of relapse-free survival (RFS) after undergoing neoadjuvant chemotherapy. To understand the molecular mechanism underlying this clinical observation, we observed that MDH2 expression was elevated in prostate cancer cell lines compared to benign prostate epithelial cells. Stable knockdown of MDH2 via shRNA in prostate cancer cell lines decreased cell proliferation and increased docetaxel sensitivity. Further, MDH2 shRNA enhanced docetaxel-induced activations of JNK signaling and induced metabolic inefficiency. Conclusion: Taken together, these data suggest a novel function for MDH2 in prostate cancer development and chemotherapy resistance, in which MDH2 regulates chemotherapy-induced signal transduction and oxidative metabolism.

    KW - chemotherapy response

    KW - docetaxel

    KW - JNK

    KW - MDH2

    KW - metabolism

    UR - http://www.scopus.com/inward/record.url?scp=84878436045&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84878436045&partnerID=8YFLogxK

    U2 - 10.1002/pros.22650

    DO - 10.1002/pros.22650

    M3 - Article

    C2 - 23389923

    AN - SCOPUS:84878436045

    VL - 73

    SP - 1028

    EP - 1037

    JO - Prostate

    JF - Prostate

    SN - 0270-4137

    IS - 10

    ER -